Cargando…

Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi

The introduction of the nine-month short-treatment regimen (STR) has drastically improved outcomes of rifampicin-resistant tuberculosis (RR-TB) treatment. Adverse events (AE) commonly occur, including injectable-induced hearing loss. In Burundi we retrospectively assessed the frequency of adverse ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciza, François, Gils, Tinne, Sawadogo, Michel, Decroo, Tom, Roggi, Alberto, Piubello, Alberto, Ortuño-Gutiérrez, Nimer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356788/ https://www.ncbi.nlm.nih.gov/pubmed/32560052 http://dx.doi.org/10.3390/jcm9061873

Ejemplares similares

High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
por: Decroo, Tom, et al.
Publicado: (2020)

Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation
por: Souleymane, Mahamadou Bassirou, et al.
Publicado: (2022)

Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence
por: Trébucq, Arnaud, et al.
Publicado: (2019)

Injectables’ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes
por: Decroo, Tom, et al.
Publicado: (2020)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study
por: Souleymane, Mahamadou Bassirou, et al.
Publicado: (2022)

Case Report: Therapeutic Threshold for Rifampicin-Resistant Tuberculosis in a Patient from Maputo, Mozambique
por: Gonzaga, Lorena D. M., et al.
Publicado: (2021)

The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance
por: Van Deun, Armand, et al.
Publicado: (2020)

Community-supported self-administered tuberculosis treatment combined with active tuberculosis screening: a pilot experience in Conakry, Guinea
por: Hassane-Harouna, Souleymane, et al.
Publicado: (2023)

Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries
por: Schwœbel, Valérie, et al.
Publicado: (2020)

Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
por: Van Deun, Armand, et al.
Publicado: (2021)

Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study
por: Hassane-Harouna, Souleymane, et al.
Publicado: (2020)

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
por: Sweeney, Sedona, et al.
Publicado: (2022)

Effectiveness and safety of bedaquiline-based, modified all-oral 9–11-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam
por: Nguyen, Thi Mai Phuong, et al.
Publicado: (2023)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

Extensively drug-resistant tuberculosis: epidemiology and management
por: Matteelli, Alberto, et al.
Publicado: (2014)

Tuberculosis: Epidemiology and Control
por: Sulis, Giorgia, et al.
Publicado: (2014)

Protocol, rationale and design of BE-PEOPLE (Bedaquiline enhanced exposure prophylaxis for LEprosy in the Comoros): a cluster randomized trial on effectiveness of rifampicin and bedaquiline as post-exposure prophylaxis of leprosy contacts
por: Younoussa, Assoumani, et al.
Publicado: (2023)

Person‐centred care and short oral treatment for rifampicin‐resistant tuberculosis improve retention in care in Kandahar, Afghanistan
por: Mesic, Anita, et al.
Publicado: (2022)

A digitalized program to improve antenatal health care in a rural setting in North-Western Burundi: Early evidence-based lessons
por: Misago, Nadine, et al.
Publicado: (2023)

An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study
por: Surey, J., et al.
Publicado: (2021)

Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda
por: Habimana, Dominique Savio, et al.
Publicado: (2021)

Psychiatric comorbidities among patients with complex drug-resistant tuberculosis in Mumbai, India
por: Laxmeshwar, Chinmay, et al.
Publicado: (2022)

Trends in tuberculosis clinicians’ adoption of short-course regimens for latent tuberculosis infection
por: Feng, Pei-Jean I., et al.
Publicado: (2023)

The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide
por: Lin, Huang-Shen, et al.
Publicado: (2016)

Moxifloxacin concentration correlate with QTc interval in rifampicin-resistant tuberculosis patients on shorter treatment regimens
por: Kusmiati, Tutik, et al.
Publicado: (2022)

Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis
por: Zhang, Zehua, et al.
Publicado: (2014)

Low Cycle Threshold Value in Xpert MTB/RIF Assay May Herald False Detection of Tuberculosis and Rifampicin Resistance: A Study of Two Cases
por: Ngabonziza, Jean Claude S, et al.
Publicado: (2021)

Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial
por: Phillips, P. P. J., et al.
Publicado: (2020)

Understanding the influence of the COVID-19 pandemic on hospital-based mortality in Burundi: a cross-sectional study comparing two time periods
por: Habonimana, D., et al.
Publicado: (2020)

Attrition one year after starting antiretroviral therapy before and after the programmatic implementation of HIV “Treat All” in Sub-Saharan Africa: a systematic review and meta-analysis
por: Makurumidze, Richard, et al.
Publicado: (2023)

Hepatotoxicity in patients co-infected with HIV and tuberculosis while receiving NNRTI-based antiretroviral regimen and rifampicin
por: Mankhatitham, W, et al.
Publicado: (2010)

Airway microecology in rifampicin-resistant and rifampicin-sensitive pulmonary tuberculosis patients
por: Cai, Xingshan, et al.
Publicado: (2022)

Blackwater Fever in Children, Burundi
por: Gobbi, Federico, et al.
Publicado: (2005)

Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial
por: Rosu, Laura, et al.
Publicado: (2020)

Inequalities in caesarean section in Burundi: evidence from the Burundi Demographic and Health Surveys (2010–2016)
por: Yaya, Sanni, et al.
Publicado: (2020)

Determinants of fertility differentials in Burundi: evidence from the 2016-17 Burundi demographic and health survey
por: Nibaruta, Jean Claude, et al.
Publicado: (2021)

Efficacy of directly observed treatment short-course intermittent regimen in spinal tuberculosis
por: Valsalan, Rejith, et al.
Publicado: (2012)

What’s Next for the Standard Short-Course Regimen for Treatment of Multidrug-Resistant Tuberculosis
por: Campbell, Jonathon R., et al.
Publicado: (2019)

Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
por: Dooley, Kelly E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rqd4nru1ch7u9iekgaa9eaqbcn